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Abstract: The number of new psychoactive substances (NPS) on the illicit drug market increases fast,
posing a need to urgently understand their toxicity and behavioural effects. However, with currently
available rodent models, NPS assessment is limited to a few substances per year. Therefore, zebrafish
(Danio rerio) embryos and larvae have been suggested as an alternative model that would require less
time and resources to perform an initial assessment and could help to prioritize substances for subse-
quent evaluation in rodents. To validate this model, more information on the concordance of zebrafish
larvae and mammalian responses to specific classes of NPS is needed. Here, we studied toxicity and
behavioural effects of opioids in zebrafish early life stages. Synthetic opioids are a class of NPS that
are often used in pain medication but also frequently abused, having caused multiple intoxications and
fatalities recently. Our data shows that fentanyl derivatives were the most toxic among the tested opioids,
with toxicity in the zebrafish embryo toxicity test decreasing in the following order: butyrfentanyl>3-
methylfentanyl>fentanyl>tramadol> O-desmethyltramadol>morphine. Similar to rodents, tramadol as
well as fentanyl and its derivatives led to hypoactive behaviour in zebrafish larvae, with 3-methylfentanyl
being the most potent. Physico-chemical properties-based predictions of chemicals’ uptake into zebrafish
embryos and larvae correlated well with the effects observed. Further, the biotransformation pattern of
butyrfentanyl in zebrafish larvae was reminiscent of that in humans. Comparison of toxicity and be-
havioural responses to opioids in zebrafish and rodents supports zebrafish as a suitable alternative model
for rapidly testing synthetic opioids.
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Abstract 
The number of new psychoactive substances (NPS) on the illicit drug market increases fast, posing a 
need to urgently understand their toxicity and behavioural effects. However, with currently available 
rodent models, NPS assessment is limited to a few substances per year. Therefore, zebrafish (Danio 
rerio) embryos and larvae have been suggested as an alternative model that would require less time 
and resources to perform an initial assessment and could help to prioritize substances for subsequent 
evaluation in rodents. To validate this model, more information on the concordance of zebrafish larvae 
and mammalian responses to specific classes of NPS is needed. Here, we studied toxicity and 
behavioural effects of opioids in zebrafish early life stages. Synthetic opioids are a class of NPS that 
are often used in pain medication but also frequently abused, having caused multiple intoxications and 
fatalities recently. Our data shows that fentanyl derivatives were the most toxic among the tested 
opioids, with toxicity in the zebrafish embryo toxicity test decreasing in the following order: 
butyrfentanyl>3-methylfentanyl>fentanyl>tramadol> O-desmethyltramadol>morphine. Similar to 
rodents, tramadol as well as fentanyl and its derivatives led to hypoactive behaviour in zebrafish 
larvae, with 3-methylfentanyl being the most potent. Physico-chemical properties-based predictions of 
chemicals’ uptake into zebrafish embryos and larvae correlated well with the effects observed. Further, 












Comparison of toxicity and behavioural responses to opioids in zebrafish and rodents supports 
zebrafish as a suitable alternative model for rapidly testing synthetic opioids. 













New psychoactive substances (NPS), also called “designer drugs”, are emerging in the illicit drug 
market at a fast pace. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
has recorded more than 730 NPS, of which 50% were detected just in the last five years. Synthetic 
cannabinoids (30%), cathinones (30%) and opioids (5%) are the main groups of NPS that have been 
recorded and monitored (EMCDDA, 2015). Although synthetic opioids represent only a small 
proportion of all NPS known to EMCDDA, they are of special concern for three main reasons: (a) 
opiates and opioids are often prescribed for pain relief (Vardanyan and Hruby, 2014), leading to their 
high use both licitly and illicitly; (b) they are highly potent, thus only a small error in dosage can result 
in a lethal overdose (Gergov et al., 2009); (c) clandestine laboratories often produce synthetic 
analogues which have no medical use and are frequently sold under the guise of, for example, heroin 
(Turock et al., 2009; Breindahl et al., 2016). In the late 1990’s, opioid prescriptions as pain 
medications increased significantly, resulting in a steady rise in opioid consumption in tandem with 
overdose and addiction problems  (Dowell et al., 2016; Jones et al., 2018). 
Opioids act primarily by binding to the mu (µ), kappa (κ) or delta (δ) opioid receptors and can produce 
analgesic effects, anaesthetic effects, sedation and drowsiness (Benyamin et al., 2008; Byas-Smith et 
al., 2005; Hug, 1992; Mahesh Trivedi, 2007). Even for opioids mainly acting by binding to the mu 
receptors only, there are differences. Opioids display varying overall potencies, for example, with 
regard to the achieved analgesic profiles. This can be explained by, e.g., differences in the affinity and 
efficacy at the receptor. Thus, opioids have been categorized into low, medium and high potency 
opioids (Drewes et al., 2013). The major concerns in the opioid abuse are associated with the high 
potency synthetic opioids. In the United States and Canada, the current opioid epidemic is being 
driven by the use of synthetic opioids, particularly fentanyl derivatives. The fast growing market of 
synthetic opioids, their easy availability and lack of information on their effects pose a range of 
challenges for public health and drug policy as well as for the drug monitoring systems for their 
inclusion in routine drug testing (EMCDDA, 2015). Data on toxicity and mechanisms of action are 












information available from animal toxicity tests or human user experience, which could allow judging 
on their potency (Pantano et al., 2019). Due to limited funds and the time and resource-intensive 
nature of rodent-based toxicity tests, only a few additional substances per year can be subjected to 
toxicological characterization. This is clearly insufficient, given the fast pace of NPS introduction on 
the market and their growing availability to global users (Dignam et al. 2017; Elliott et al. 2017). 
While in vitro tests could provide additional means for rapid testing of some endpoints, they are at 
present not yet able to replace testing for complex effects which may occur in drug users, such as 
behavioural responses, chronic toxicity, and developmental toxicity. Therefore, it would be beneficial 
if there were an alternative animal model representative of whole-animal responses, which would 
allow testing the NPS toxicity more quickly and efficiently than is currently possible with rodents.  
Such alternative approach could involve testing with zebrafish embryos and early larvae, which have 
been gaining popularity as a test organism complementing rodents in understanding the pharmacology 
of drugs, especially for toxicity and behavioural effects. Early life stages of zebrafish, spanning the 
period from fertilization to the start of independent feeding, are considered to be an alternative, non-
animal test system. This model has a variety of applications in human hazard assessment, including 
acute systemic toxicity (Ali et al., 2011; Lammer et al., 2009; Padilla et al., 2012), chronic toxicity 
(Volz et al., 2011), teratogenicity (Gustafson et al., 2012; Selderslaghs et al., 2009), neurobehaviour 
(Kokel et al., 2010; Selderslaghs et al., 2010) and specific organ toxicities (Berghmans et al., 2008; 
Parng et al., 2002). Zebrafish and mammals have highly conserved pharmacological targets (Rinkwitz 
et al., 2011; Howe et al., 2013). Studies have shown high similarity of fish and mammalian responses 
to small molecules that cause reproductive toxicity, behavioural effects, teratogenicity, 
carcinogenicity, cardiotoxicity, ototoxicity, or liver toxicity (Caballero, 2018; Eimon and Rubinstein, 
2009; Kithcart and MacRae, 2017; Levin et al., 2003; Milan et al., 2003; Parng et al., 2002)  
The expression and function of opioid receptors in zebrafish have been shown to be both biologically 
and pharmacologically comparable to mammals, including rodents and humans. Moreover, zebrafish 
opioid receptor transcripts could be detected early in the development (before 3 hours post 












perception has been well studied in fish, including zebrafish, and behavioural studies are often used as 
indicators to study pain  (Mettam et al., 2011; Reilly, 2008; Sneddon, 2009). 
As part of the research focused on the potential use of the zebrafish model for toxicological 
characterization of NPS, the aim of the present study was to assess the toxicity and behavioural 
responses to opioids in the early life stages of zebrafish. By testing several opioids belonging to 
different potency categories, we addressed the following research questions: (a) whether opioids elicit 
similar or differing toxicity and behavioural effects in the early stages of zebrafish compared to 
mammals; (b) whether the opioids with varying potencies in mammals follow the same pattern in 
zebrafish and (c) whether there are similarities in the biotransformation of opioids between zebrafish 












Materials and Methods 
Selection and acquisition of test compounds 
We chose six opioids representing low, medium and high potency categories to assess their toxicity 
and behavioural effects in zebrafish larvae. These substances included morphine, a naturally derived 
opioid, chosen as a classical medium potency opioid with a long history of both licit and illicit use. 
Further, tramadol and its metabolite, O-desmethyltramadol, were chosen as low potency opioids and 
also due to tramadol’s mixed mode of action. Tramadol’s actions on the opioid receptors are mediated 
by its metabolite O-desmethyltramadol, while Tramadol itself acts on the monoamine 
neurotransmission (Meyer et al., 2015). Therefore, we were interested in assessing the differences in 
the effects of tramadol and O-desmethyltramadol in zebrafish larvae. Finally, three fentanyl 
derivatives were chosen as high potency opioids. Three out of the five most harmful synthetic opioids 
listed by EMCDDA belong to the fentanyl group. For the three fentanyl drugs that we have selected, 
several intoxications have been reported in the recent years. These substances included fentanyl itself, 
which is a synthetic licit and illicit opioid, 3-methylfentanyl, which has the strongest analgesic potency 
of all fentanyls, and butyrfentanyl, which has caused several deaths, including a case documented at 
our institute (Staeheli et al., 2016).  Based on their high octanol-water partition coefficient and the 
inherent high potency, we assumed that fentanyl and derivatives (i.e., butyrfentanyl and 3-
methylfentanyl) should demonstrate the highest toxicity in zebrafish. Based on the effects of opioids in 
mammals, we assumed that, like rodents, zebrafish larvae should respond with hypoactive behaviour 
to treatment with opioids.  
The list of chemicals including their physico-chemical properties is provided in Table 1 and their 
chemical structures are given in Figure 1. All six chemicals had analytical purity >98.5%; they were 
obtained from Lipomed (Arlesheim, Switzerland) with the permission from the Swiss Federal Office 
for Public Health to use controlled substances. For drug exposures, stock solutions were prepared in an 













Zebrafish (Danio rerio) of OBI wild-type strain (Leipzig, Germany) and wild mix background were 
maintained at 28°C under a 14-h light/10-h dark cycle. Fish were reared in recirculating flow-through 
systems filled with a mix of desalted and tap water, treated with active carbon filter and UV light. 
Zebrafish were fed with a combination of live artemia and dry flakes twice daily. Eggs for exposure 
studies were collected from group crosses and were either exposed immediately for early exposures or 
maintained in reconstituted water (294.0 mg/l CaCl2.2H2O, 123.2 mg/l MgSO4.7H2O, 64.74 mg/l 
NaHCO3 and 5.75 mg/l KCl) until 5 days post fertilization (dpf) in a Petri dish (ca. 50 embryos per 
dish), placed in an incubator with the same conditions as mentioned above. All procedures were in 
accordance with the animal protection guidelines and were approved by the Swiss Cantonal Veterinary 
Office.  
Zebrafish embryo toxicity test (zFET) 
zFET test was performed in triplicate according to the Organisation for Economic Co-operation and 
Development (OECD) Test Guideline 236 with a few modifications. Concentrations for the zFET test 
were chosen from an initial range-finding test (RFT) which was performed as a single replicate. The 
concentrations assessed in both tests for each chemical are shown in the supplementary table S1. For 
the RFT, 10 eggs per chemical concentration, and 20 eggs for the negative (blanc) control, were 
exposed in a 96-well plate (one egg per well in 0.5 mL solution) from approximately two-cell stage to 
120 hours post fertilization (hpf) without renewing the drug solutions. For the zFET tests, 10 eggs per 
concentration, including a negative (blanc) control, were exposed starting at approximately two- to 
sixteen-cell stage in a 24-well plate (one egg per well in 1 mL solution). Each day, exposure solutions 
were replaced with freshly prepared solutions. The embryos were monitored from 24 hpf to 120 hpf, 
which corresponds to 1 day post fertilization (1dpf) and 5 dpf, respectively. Mortality and 
developmental abnormalities were recorded to calculate the lethal (LC50) and sublethal (EC50) metrics, 
respectively. 












A maximum non-toxic concentration (MNTC) was calculated for each test compound based on the 
short-term exposure test where larvae of 4 dpf were exposed for 24 h. The tests were performed in 
duplicates. At 5 dpf, larvae were monitored for any abnormalities and MNTC was defined as the 
concentration at which no significant effects were observed. The MNTC was then used to determine 
the maximum safe concentration that could be tested in the locomotor behaviour assessment, where 
test concentrations were chosen such that the MNTC was not surpassed.   
Locomotor behaviour assessment 
In the morning, unexposed larvae aged 5 dpf were distributed one larva per well in a 48-well plate 
with well volume of 500 µl and then acclimatized for three h in the housing incubator. After 
acclimatization, the test chemical was added and larvae were immediately placed on the recording 
platform for tracking the locomotor activity. Locomotor activity was assessed using the ZebraLab
TM
 
behaviour tracking system (Version 3, View Point, Lyon, France) consisting of a video camera of 25 
frames per second. Detection threshold was set to 20 for tracking the animal excluding any 
background. The protocol consisted of 70 min tracking with light and dark phases alternating every 10 
min starting with light. Data were exported and analysed for every two min integration period.  
Prediction of internal opioid concentrations 
The bioconcentration factor (BCF) and time to reach steady-state (tsss) in the larvae were predicted for 
all test chemicals using previously described models (Hendriks et al., 2001; Stadnicka et al., 2012; 
Kirla et al., 2016). To investigate if zebrafish larvae can biotransform tramadol to O-
desmethyltramadol at the conditions used for behaviour experiments, larvae were frozen after 70 min 
of drug exposure and analysed for tramadol and O-desmethyltramadol by LC-MS/MS using the 
method described in (Staeheli et al., 2016). To study the uptake kinetics and biotransformation 
patterns for butyrfentanyl, exposed larvae were pooled and frozen at different time points (16 larvae 
per time point). On the day of analysis, frozen larvae samples were thawed, homogenized, extracted 
with acetonitrile and analysed by LC-MS/MS method developed previously (Staeheli et al., 2016). A 













All data were exported and analysed using Microsoft Excel 2010. All graphs were plotted in GraphPad 
Prism® (Version 6 for Windows, GraphPad software, San Diego, California, USA). For the zFET test, 
lethal and sublethal concentrations were calculated using sigmoidal four parameter dose-response 
curves in GraphPad Prism
®
 6. For the locomotor activity assessment, statistical analysis was 
performed using RStudio (Version 0.98.486, USA) following commonly agreed methods for this type 
of data (MAcPhail et al., 2009). In more detail, data were segregated into light and dark subsets and 
Repeated Measures Analysis of Variance was performed for each subset at each lighting condition. 















Lethal and sublethal effects in zebrafish embryo toxicity test  
LC50 and EC50 were determined from the zFET tests (Figure 2, Table 2). 
Morphine at the tested concentrations did not cause any dose-dependent mortality in the zFET test 
(Figure 2A) or in the RFT even at the highest concentration of 25 mM (Supplementary table S1). 
There was also no developmental toxicity observed in the zFET test (Figure 2A). Therefore, no LC50 
or EC50 could be determined for morphine.  
Tramadol did not cause mortality in the zFET test. Therefore, LC50 was determined from the RFT 
(Figure 2B), where lethal effects such as egg coagulation and lack of heartbeat were observed. Sub-
lethal effects, such as deformed chorda and protruded mouth abnormalities, were observed in the zFET 
test at 50 µM and higher concentrations; these effects became apparent mostly post-hatching. At lower 
concentrations, an occasional delayed hatching was noticed. However, by 5 dpf all larvae were 
hatched.  
Similarly to tramadol, O-desmethyltramadol did not cause lethality in the zFET test and LC50 was 
calculated from the RFT (Figure 2C). Sub-lethal effects such as deformed chorda and abnormalities in 
protruded mouth were occasionally observed in the zFET test post-hatching, but no concentration-
dependent drug effects were noticed. Therefore, EC50 could not be determined for O-
desmethyltramadol.  
Exposure to fentanyl caused dose-dependent mortality in the zFET test (Figure 2D). Absence of heart 
beat was the main lethal endpoint. Cumulative mortality increased with time, especially post-hatching. 
Sub-lethal effects were observed as early as 48 hpf and steadily increased in number and severity over 
the duration of treatment. The main sub-lethal effects noted prior to hatching were pericardial oedema, 
yolk sac oedema and slower heart rate. Post-hatching, deformed chorda and abnormalities in 












Similarly, to fentanyl but with higher potency, 3-methylfentanyl caused dose-dependent mortality in 
the zFET test (Figure 2E). Egg coagulation and lack of heart beat were the main lethal effects. Sub-
lethal effects were seen already at the lowest concentration tested (0.001 µM) and increased with dose, 
affecting 100% larvae at the highest concentration of 50 µM. Arrested growth, pericardial oedema and 
decreased heart rate were observed before hatching. After hatching, deformed chorda and yolk-sac 
oedema were also detected.  
Butyrfentanyl was the most potent among the compounds tested, with the lowest LC50 value and 
100% mortality observed at the two highest concentrations tested (Figure 2F). Lack of heart beat was 
the main lethal effect observed. In contrast to 3-methylfentanyl, sub-lethal effects started occurring 
only at 5 µM and above and included pericardial oedema, malformed chorda, arrested growth and 
slowed heartbeat.  
Short term toxicity test to determine maximum non-toxic concentration 
To determine the maximum non-toxic concentration (MNTC) to be used in locomotor behaviour 
experiments, a short-term 24 h exposure was carried out starting at 4 dpf (Figure S1). For morphine, 
this test was not performed as there were no morphological effects observed from zFET test and 
therefore a 50 µM concentration was used as highest for behavioural studies. For tramadol, no effects 
were observed at all concentrations tested except for one embryo at the highest concentration 
(Supplementary figure S1A). Similarly, O-desmethyltramadol exposed larvae showed no effects at any 
tested concentrations during the 24 h exposure (Supplementary figure S1B). Larvae treated with the 
highest concentration of fentanyl showed pericardial oedema and yolk sac oedema, while no effects 
were observed at lower concentrations (Supplementary figure S1C). A short-term exposure to 3-
methylfentanyl caused mortality at 15 and 25 µM treatments and resulted in abnormalities at 10 µM 
and above, which included pericardial oedema, irregular heart-beat, yolk-sac oedema and deformed 
head and chorda (Supplementary figure S1D). Butyrfentanyl at10 µM and higher caused sub-lethal 













Effects on the behaviour were assessed by monitoring the locomotor activity of the larvae (Figure 3). 
The concentration that starts to produce a significant behaviour effect was termed the lowest 
significant behaviour effect concentration (LSBEC) (Table 2). To determine the impact of morphine 
and tramadol on the behaviour of zebrafish larvae, locomotor activity was assessed for two different 
concentration ranges, low and high. Morphine did not significantly alter the locomotion at any tested 
concentration (Supplementary table S2A), neither in the low (Supplementary figure S2) nor high 
(Figure 3A) range. Therefore, LSBEC could not be determined for morphine. The locomotor activity 
of tramadol exposed larvae decreased at the high concentration range with the impact being significant 
at concentrations ≥ 1 µM (Figure 3B) (Supplementary table S2B). In the low concentration range (i.e., 
˂ 1 µM), no significant changes in the activity were induced (Supplementary figure S3). O-
desmethyltramadol did not significantly alter the locomotion of the larvae at any tested concentration 
(Figure 3C, supplementary table S2C). Therefore, the LSBEC of O-desmethyltramadol could not be 
determined. Fentanyl significantly reduced the locomotor activity of the larvae at 1 µM and above, 
mainly under the stimulus condition, i.e. dark (Figure 3D, Supplementary table S2D). 3-
methylfentanyl produced significant reduction in the locomotor activity in a dose-dependent manner, 
starting at 0.01 µM (Figure 3E) both in the light and dark conditions (Supplementary table S2E). 
Butyrfentanyl significantly reduced the locomotor activity in a dose-dependent manner starting at 1 
µM in the dark (Figure 3F, Supplementary table S2F).  
Bioconcentration factor and steady state predictions 
The BCF and time to reach steady-state (tss) that were predicted for the tested opioids based on their 
physico-chemical properties and using a one-compartment toxicokinetic model are shown in Table 2. 
A relationship between the logD values of the chemicals and the predictions made could be observed, 
that is, in general, with the decreasing logD values (Table 1), their predicted BCF decreases while time 













Uptake and biotransformation  
In mammals, analgesic activity of tramadol is mainly driven by its metabolite O-desmethyltramadol 
(Meyer et al., 2015). In our study, when we observed the toxic and behavioural effects of these 
compounds separately, it was not clear whether the effects seen from tramadol were caused by itself or 
its biotransformation product. Therefore, we analysed whether zebrafish larvae can biotransform 
tramadol. To analyse biotransformation of tramadol to O-desmethyltramadol, zebrafish larvae were 
exposed for 70 min to the high range of tramadol concentrations similar to those used for locomotor 
activity assay. With increasing exposure concentration, internal concentration of tramadol increased. 
However, O-desmethyltramadol was not detected in any of the analysed samples (Supplementary table 
S3). The limit of quantification (LOQ) was about 0.001 µM for O-desmethyltramadol. The lowest 
concentration of tramadol that could be measured was 10 times higher than the LOQ of O-
desmethyltramadol. 
Butyrfentanyl biotransformation was studied in zebrafish larvae in order to compare the pattern to that 
in humans as analysed in blood samples and in a documented post-mortem case at our institute 
(Staeheli et al., 2016). For this, we studied the uptake of butyrfentanyl by exposing the zebrafish 
larvae to 5 µM and quantifying the internal concentrations over time. Butyrfentanyl was quantifiable 
in the whole-body homogenates from the first measured time point (30 min). The uptake increased 
gradually, reaching steady-state around 6 h, with an internal concentration of 165 ± 5 mg/kg (Figure 
4). The experimental data on the uptake fits well with the predicted uptake based on the pH corrected 
octanol-water partition coefficient, that assumes passive uptake of butyrfentanyl. Zebrafish larvae 
biotransformed butyrfentanyl by oxidation to hydroxy-butyrfentanyl followed by conjugation to the 
corresponding glucuronide (Figure 4). Over the studied time interval, about 8-26% of the parent 
compound taken up underwent oxidation and 1-9% underwent glucuronidation while the rest remained 















Correlation of physico-chemical properties to the toxic effects observed 
No significant lethal and sublethal effects upon morphine treatment in zebrafish embryos/larvae was 
observed, likely due to the low uptake rate during aqueous exposure, suggested by the low pH-
corrected octanol-water partition coefficient of this compound. The uptake could also be influenced by 
the speciation of morphine, which depends on the pH and temperature. At physiological pH and the 
exposure temperature (28ºC), charged species (HOBNH
+
) of morphine would dominate, affecting 
morphine permeation through the membranes (Stevens and Balahura, 2007). Low uptake of morphine 
administered in exposure water has been reported in goldfish with uptake being less than 1% of the 
amount present in water (Newby et al., 2009). Compound uptake in the zebrafish embryo increases 
with increasing lipophilicity of the respective chemical leading to high internal concentrations (de 
Koning et al., 2015). Sulfamethoxazole, which has a logP (0.79) close to that of morphine and, like 
morphine, predominantly exists in ionic form under the exposure pH (7.4), similarly resulted in very 
low uptake with a relative internal concentration of 0.18 compared to the external medium 
concentration (Brox et al., 2016). The predicted BCF and tss of morphine (Table 2) also agrees with its 
low accumulation in zebrafish embryos. These findings support the notion that the lower the logP, the 
lower the substance’s likelihood to be toxic to the developing zebrafish (Padilla, 2013). Another aspect 
important for the bioavailability of the drug is its solubility. It was suggested that morphine 
hydrochloride’s solubility in exposure medium can be decreased by the presence of chloride ions in 
the medium due to common-ion effects (Stevens and Balahura, 2007).  
In a large scale toxicity assessment of compounds in zebrafish embryos and larvae exposed for 1-5 
dpf, an LC50 of 123.8 mM from 1-3 dpf and 23.39 mM at 4 and 5 dpf was obtained for morphine 
hydrochloride (Ali et al., 2011). In our study, the highest concentration tested in the range-finding test 
(25 mM) (Supplementary table S1) gave only 10% mortality at 4 and 5 dpf. While the pH of the test 
medium was the same in both studies, there are two main differences: First, and the most likely 
scenario is that, while the embryos have been exposed by 2 hpf in our study, in Ali’s study exposure 












exposure concentration in the medium, Ali and co-workers have used a static non-replacement regime 
throughout the exposure duration, meaning there was no refreshment of test solutions. They observed 
buffer loss over the exposure period, which could increase the concentration of the drug. While 
assessing the effects of morphine on the immune system in zebrafish embryos, Mottaz and coworkers 
(Mottaz et al., 2017) measured the internal concentration of morphine sulphate. Fish exposed to 1 mg/l 
(1.5 µM) of morphine from ≈1hpf to 4 dpf accumulated 11.7 ng/g (0.0117 mg/kg) wet weight. 
Assuming the similar uptake of morphine hydrochloride (1 mg/l is 3.1 µM), 4 days of exposure in our 
study would result in a maximum internal concentration of 0.3 mg/kg at 100 µM exposure or 94 mg/kg 
at 25 mM exposure, the maximum concentration tested in this study. With an oral bioavailability of 
20-40%, morphine with an LD50 of 470-745 mg/kg in rodents (Higashikawa and Suzuki, 2008) would 
need a minimum of 94 mg/kg-298 mg/kg to be lethal. In another study, only about 5% of exposed 
morphine was detected in the embryo after an exposure to 10 nM morphine from 5 hpf to 24 hpf and 
48 hpf (Sanchez-Simon et al., 2010). Comparing this 5% uptake to the present study would result in 
0.015 mg/kg internal concentration at 100 µM exposure. Thus, the internal concentrations achieved in 
zebrafish embryos in our study could have been too low to produce effects.   
In the zFET test, tramadol is more toxic in zebrafish embryos than its metabolite O-
desmethyltramadol. This is consistent with the higher logD value of tramadol than O-
desmethyltramadol, predicting lower uptake of O-desmethyltramadol into zebrafish embryo. Tramadol 
toxicity could also be exerted by a mechanism other than activation of mu opioid receptors by its 
active metabolite O-desmethyltramadol. For example, tramadol is also known to act as inhibitor of 
monoamine reuptake and as inhibitor of ligand-gated ion channels (Doostmohammadi and Rahini, 
2020), and it can also induce oxidative stress (Plhalova et al., 2020). The absence of  tramadol toxicity 
observed in our experiments at low concentrations (< 10 µM) is consistent with other studies where 
tramadol exposure up to 16.75 µM produced no lethal or sublethal effects except for delayed hatching 
reported by Sehonova et al. (Sehonova et al., 2016; Bachour et al., 2020; Plhalova et al., 2020).  
Fentanyl derivatives with the higher logP values showed higher potency. Based on the LC50 values, 












toxic than fentanyl. The physico-chemical properties-based modelling also predicted the highest 
accumulation of butyrfentanyl, followed by fentanyl and 3-methylfentanyl. While the logP values of 
fentanyl, 3-methylfentanyl and butyrfentanyl do not differ much, the additional difference in their 
toxicities could be due to differential receptor affinity and thereby different potency. Compared to all 
tested chemicals, butyrfentanyl and 3-methylfentanyl showed most severe toxicity from 24-48 hpf 
(data not shown), reflecting their likely effects on the development of heart, brain and bilateral 
organization, which are the major events happening during embryo development at these stages 
(Kimmel et al., 1995). The pericardial oedema of the larvae, which was observed for all fentanyls, 
might have resulted from the homeostasis imbalance due to the failure of water permeability barrier. 
This toxic response has also been observed upon exposure of embryos to other chemicals, including 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Hill et al., 2004).  
Behavioural effects of opioids in zebrafish larvae 
Morphine had no effects on the locomotor activity in zebrafish larvae at 5 dpf. This result is consistent 
with previous findings at comparable concentrations tested (Ali et al., 2012). However, these authors 
observed a biphasic response in the locomotor activity, visible only at concentrations ≥3 mM, i.e. 
initial excitation at 3-12 mM followed by sedation at much higher concentrations of ≥12 mM. 
However, it has to be emphasized that the exposure setups used in the two studies are very different, 
with their chronic (96 h) exposure and 70 min exposure in our study. In another study with a more 
comparable exposure period of 1h, which analysed the choice-behaviour in 2 week old larvae, 
morphine at 0.8 µM (within our low concentration test range of 0.5-5 µM) did not alter the swimming 
activity (Bretaud et al., 2007). Therefore, the morphine concentration reached at target sites during the 
70 min exposure duration might have been too low to cause any changes in locomotor activity.  
The measured outcome of locomotor activity shows tramadol to be more potent in zebrafish larvae 
compared to its metabolite O-desmethyltramadol. In mammals, O-desmethyltramadol produced as a 
metabolite of tramadol is known to be 200 times more potent than the parent compound because of its 
higher affinity to opioid receptors (Meyer et al., 2015). However, when we administered O-












activity. There could be at least two explanations. The first possibility is that, in mammals, O-
desmethyltramadol is produced internally as a metabolite of tramadol in vivo. However, in our work, 
O-desmethyltramadol itself was administered as a drug. Therefore, as discussed above, a too low 
uptake of this compound could have precluded the observation of any effects. The other possibility 
concerns the mixed mechanism of action of tramadol. Both tramadol and O-desmethyltramadol are 
centrally acting opioid analgesics. In addition, tramadol can interfere with serotonin neurotransmission 
in a way similar to drugs such as meta-chlorophenylpiperazine (mCPP) (Kirla et al., 2018) and para-
methylthioamphetamine (Gobbi et al., 2002). In our previous study (Kirla et al., 2018), we observed a 
decreased locomotor activity in zebrafish larvae exposed to mCPP, which is a serotonin receptor 
agonist and serotonin reuptake inhibitor. Therefore, tramadol induced hypoactive behaviour in 
zebrafish larvae could be driven via the serotonin neurotransmission system rather than via the opioid 
system. This is also supported by tramadol’s weaker affinity to mu (µ) opioid receptor, which is the 
predominantly expressed receptor in the larval stage (Sanchez-Simon and Rodriguez, 2008; Gonzalez-
Nunez and Rodriguez, 2009).  
Of all the opioids tested, 3-methylfentanyl had the highest potency for reducing the locomotor activity 
of the larvae. The fentanyl-based series of compounds are among the most potent analgesics because 
of their highly selective affinity to mu (µ) opioid receptors (Bagley et al., 1991; Vardanyan and 
Hruby, 2014). Moreover, changes in the scaffold structure of fentanyl results in different biological 
and pharmacological activities. A 3-methyl substitution at the third position of the piperidine ring 
causes a sharp increase of µ-affinity and selectivity. This increases the potency of 3-methylfentanyl to 
cause hypoactive behaviour in zebrafish larvae. To summarize, the behavioural effects of different 
opioids tested in zebrafish shows that fentanyl derivatives, 3-methylfentanyl followed by butyrfentanyl 
are the most potent opioids with regard to behavioural effects.  
Evaluation of concordance between zebrafish larvae and mammals 
The potencies of all tested chemicals were compared to that of fentanyl, as is frequently performed in 
rodents. To compare the toxicity between zebrafish larvae and mammals, LC50 values were used 












rodents (Fidecka et al., 1978). The analgesic effect of opioids is known to also result in sedation and 
thereby have less activity in rodents (Craft et al., 2006; Taylor et al., 2016). Therefore, we compared 
the behavioural effects measured in zebrafish larvae to the analgesic potency in mammals (Table 4). 
For this, the lowest concentration that altered the locomotor activity in the larvae, i.e., the LSBEC, was 
compared to the effective analgesic dose (ED50) in mammals.  
Morphine effects on the locomotion in rodents are varied. One study reported a biphasic response, 
with 1-10 mg/kg showing excitation and a higher concentration of 32 mg/kg showing decreased 
activity upon intraperitoneal injection (Li et al., 2013). In contrast, in another study that also reported a 
biphasic response with 1-10 mg/kg morphine administered subcutaneously, an initially suppressed and 
later increased locomotor activity was observed (Craft et al., 2006). Other studies showed no 
significant alterations in locomotion at 4-7 mg/kg upon intraperitoneal injection (Rezayof et al., 2009; 
Rezayof et al., 2013). Nevertheless, as discussed above, results from the study of continuous morphine 
exposure in zebrafish embryos at much higher concentrations suggest that morphine can induce 
behavioural effects, but only at the concentrations higher than tested here (Ali et al., 2012). 
In zebrafish larvae, lethality with tramadol was not observed in the zFET test; however, mild sub-
lethal effects were noted. Tramadol use during early pregnancy in humans has been reported to be 
non-lethal to the developing foetus. However, 0.05% of infants showed congenital malformations such 
as cardiovascular defects and defective foot (Bloor et al., 2012; Källén and Reis, 2015). The LD50 
potency ratio of tramadol compared to fentanyl in zebrafish larvae is close to the range found in 
rodents (Table 4). However, the ratio of the concentration producing hypoactivity to fentanyl is 500 
times higher in zebrafish larvae compared to the analgesic dose in rodents (Table 4). For tramadol, the 
hypoactive behaviour and analgesic activity could be different because the analgesic activity is known 
to be mediated by tramadol’s active metabolite O-desmethyltramadol (Meyer et al., 2015). However, 
when we analysed for O-desmethyltramadol in the tramadol exposed larvae during 70min, no O-
desmethyltramadol could be found; even the LOQ of O-desmethyltramadol being 10 times lower 













3-methylfentanyl LD50 in rodents is two times lower (Mefentanyl) than the LC50 observed in zebrafish 
larvae, what can be considered comparable, especially given the different route of administration in 
rodents and zebrafish. Butyrfentanyl toxicity in zebrafish and mammals could not be compared to 
LC50 of fentanyl because of the lack of data on their LD50 in rodents. In mammals, butyryl substitution 
is supposed to have lower opioid potential than fentanyl itself. However, we observed that during 
development, butyrfentanyl resulted in higher lethality than fentanyl. This suggests that the 
developmental stages of an organism could be more sensitive to the toxic effects of these chemicals 
compared to the fully developed organism. Fentanyl is used for pain treatment during pregnancy in 
humans and animals. Developmental effects and neonatal effects of fentanyl have been reported from 
clinical studies as well as case studies. The adverse events and toxicities that were reported have 
occurred due to respiratory depression, cardiovascular effects and neuronal-related events such as 
seizures, effects on eye and brain coordination (Ancora et al., 2017; Hardwick et al., 1997; Muller and 
Vogtmann, 2000; Ostwal et al., 2015). 
The span between lethality and sub-lethality causing concentrations (i.e., LD50 and ED50 values) of 
butyrfentanyl and 3-methylfentanyl is very narrow, suggesting a high risk when consumed 
(Higashikawa and Suzuki, 2008). In humans, several intoxication cases are known to have resulted 
from the consumption of butyrfentanyl (Bäckberg et al., 2015; Staeheli et al., 2016) and 3-
methylfentanyl (Martin et al., 1991; Ojanpera et al., 2006; Ojanpera et al., 2008). The narrow span 
between lethal and sub-lethal concentrations of fentanyl derivatives is perfectly reflected in the 
zebrafish model as well, with LC50 and EC50 differing by less than 30% in the case of butyrfentanyl 
and by only 2 times for 3-methylfentanyl (Figure 2). Another reason for the deaths associated to 
fentanyl and its derivatives is the adulteration of the illicit traditional drugs with these high potent ones 
(Algren et al., 2013). This is also one of the main contributors to the ongoing opioid epidemic. 
Hypoactive behaviour induced by fentanyl in zebrafish larvae is concordant to the suppression of the 
locomotor activity in rodents in an open-field exploration test after intraperitoneal injection (Fidecka et 
al., 1978). Opioid receptor expression has been studied at early developmental stages in zebrafish and 
homology to the mammalian opioid system was found to a large extent (Gonzalez-Nunez and 












leading to hypoactive behaviour can be explained by their analgesic and sedative actions upon binding 
to the opioid receptors. When compared to fentanyl, the analgesic potency in rodents and potency to 
cause hypoactivity in zebrafish larvae is the highest for 3-methylfentanyl (Table 4). The potency ratio 
to fentanyl, however, is about 10 times higher for 3-methylfentanyl and 7 times higher for 
butyrfentanyl in zebrafish larvae than in rodents.  
The uptake of butyrfentanyl in zebrafish larvae is driven by passive diffusion processes as supported 
by the similarity of the predicted and measured internal concentration values. The biotransformation of 
butyrfentanyl majorly by phase-I to OH-butyrfentanyl and phase-II to glucuronide in zebrafish larvae 
is similar to OH-butyrfentanyl observed in authentic human samples and OH- butyrfentanyl and 
butyrfentanyl-glucuronide observed in a post-mortem case. CYP2D6 and CYP3A4 are suggested to be 
the main enzymes involved in the biotransformation of butyrfentanyl. In the post-mortem case, 
carboxy-butyrfentanyl was also found as a major metabolite (Staeheli et al., 2016; Steuer et al., 2016). 
However, it has been suggested that the carboxy- butyrfentanyl producing pathway is activated only as 
an alternative if CYP3A4 is inhibited. Thus, under natural conditions of CYP3A4 function, this 
metabolite would not have been produced. We have looked for carboxy- butyrfentanyl in zebrafish 
larvae as well, but could not detect it, suggesting that in live zebrafish larvae, CYP3A4 function was 
normal.  
In conclusion, zebrafish embryos and larvae are sensitive to synthetic opioids with toxicity and 
behavioural effects comparable to rodents. Moreover, the low, medium and high potency opioids show 
similar response patterns in zebrafish and mammals, and biotransformation of butyrfentanyl was also 
comparable. Thus, zebrafish model can be used to gain information on the developmental effects of 
opioids, occurring when pregnant women use them for pain medication or abuse them. Further, this 
test organism may be used to assess opioid-adulterated drug suspects, frequently contributing to the 
recently observed increase in drug-related deaths. When the potencies were compared with fentanyl 
taken as a reference, differences were seen especially for the analgesic versus locomotor activity 
effects with zebrafish larvae being more sensitive than rodents. Because of the different routes of 












studies could aid in explaining the differences. Here, characterization of the internal concentrations 
and distribution kinetics might provide a clue for the observed differences between the organisms. 
Overall, zebrafish early stages appear to represent a promising model for early screening of NPS 
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Table 1: Physico-chemical properties of opioids used in this study. The logarithm of the octanol/water partition 
coefficient (logP) is a measure of lipophilicity. LogD describes lipophilicity at pH 7.4. The estimates for the 
dissociation constant (pKa) are given for the strongest basic site. 
 
a Prediction from EPI SuiteTMsoftware (Version 4.1, U.S. Environmental Protection Agency) 
b Prediction from Advanced Chemistry Development, Inc. (ACD/Labs), Toronto, Canada 
c Prediction from ChemAxon, DrugBank (Version 5.0) 
  
Compound CAS number Referred to in 
this work as 
Molecular weight 
(g/mol) 
log Pa log Db pKac 
Morphine HCl.monohydrate 52-26-6 morphine 339.8 0.72 -0.13 9.12 
Tramadol HCl 36282-47-0 tramadol 299.84 3.01 0.52 9.23 
O-Desmethyl-cis tramadol HCl 1018989-94-0 O-
desmethyltramadol 
285.81 2.45 0.07 8.97 
Fentanyl citrate 990-73-8 fentanyl 528.6 3.89 3.01 8.77 
d, l-cis 3-Methylfentanyl HCl 42045-86-3 3-methylfentanyl 386.96 4.31 2.88 9.08 














(μM)  CI_95 
EC_50 







Morphine n.a.   n.a.   n.a. 0.9 35.4 






n.a.   n.a. 0.98 
23.3 
Fentanyl 83.1 67.8-102.0 16.1 10.8-24.2 1 51.9 1.6 
3-methylfentanyl 13 8.7-19.6 6.3 5.3-7.6 0.01 38.7 1.5 
Butyrfentanyl 7.5 6.2-9.1 5.9 5.1-6.9 1 102.8 1.7 
*As lethality could not be determined from the zFET test, LC50 values for these two chemicals were obtained 
from a range-finding test conducted as a single replicate. 
Table 2: Overview of data collected in the course of this study. The shown values include the experimentally 
measured lethal (LC50) and sub-lethal (EC50) toxicity and the lowest significant behaviour effect concentration 
(LSBEC) values, as well as bioconcentration factor (BCF) and time to steady-state (tss) predicted by modeling. 
LC50 and EC50 were determined from the zebrafish embryo toxicity test (zFET) and behaviour was assessed by 
tracking the locomotor activity of the larvae, both tests performed in triplicates. LC50 and EC50 values are 
presented as mean with confidence intervals (CI95). Note that LC50 and EC50 for morphine and EC50 for O-
desmethyltramadol could not be determined as no respective effects were observed neither in the zFET test nor 
in the range-finding test.  For tramadol and its metabolite O-desmethyltramadol, LC50 values were calculated 
from a range-finding test conducted as a single replicate, because no mortality was observed in the zFET test. 














Opioid LD50 in rodents, 
mg/kg 
LC50 in zebrafish, 
μM  












Oral: 0.17-0.2,  
IV: 0.03-0.06  0.037 
O-







e 83.1 1 1 
3-methylfentanyl IP: 24.8
f
 13 3.1 6.35 
Butyrfentanyl n.a 7.5 n.a 14.34 
a. (Higashikawa and Suzuki, 2008)  
b. (Ali et al., 2011) 
c. (Matthiesen et al., 1998) 
d. (DrugBank) 
e. (Fentanyl)  
f. (Mefentanyl)  
 
Table 3: Comparison of the lethal concentrations of different opioids to fentanyl in rodents and zebrafish larvae. 
LD50 or LC50 ratio to fentanyl is obtained by dividing the LD50 or LC50 of fentanyl to the LD50 of each chemical 

















LSBEC (μM) in 
zebrafish  














 n.a 0.002 n.a. 
Fentanyl 0.006
a
 1 1 1 
3-methylfentanyl 0.00058-0.0068
a
 0.01 0.9-10.5 100 
Butyrfentanyl 0.047
a
 1 0.13 1 
a. (Higashikawa and Suzuki, 2008) 
b. (Hennies et al., 1988) 
c. (Dursteler et al., 2006) 
Table 4: Comparison of the analgesic potency of opioids to fentanyl in rodents and lowest significant behaviour 
effective concentration (LSBEC) to fentanyl in zebrafish larvae. Potency ratio to fentanyl is obtained by dividing 































Figure 1: Chemical structures of the tested opioids. (A) morphine; (B) tramadol; (C) O-desmethyltramadol; 
(D) fentanyl; (E) 3-methylfentanyl; (F) butyrfentanyl. Morphine (A) is a naturally occurring alkaloid containing 
a 4, 5-epoxymorphinan ring. Tramadol (B) and its metabolite O-desmethyltramadol (C) belong to the 3-amino-1-
phenylpropan-1-ol series. Fentanyl (D) and its derivatives belong to the anilidopiperidine series; methyl 
substitution on the piperidine ring at 3
rd
 position gives 3-methylfentanyl (E) and butyryl group instead of 
































Figure 2: Developmental toxicity of opioids. Zebrafish embryo toxicity (zFET) test was performed to 
determine the lethal (LC50) and sub-lethal (EC50) concentrations by exposing embryos to different opioids (A-F) 
from 0-5 days post fertilization (dpf) and monitoring the mortality and abnormalities. Data were obtained from 
three independent replicates with 10 embryos per treatment per replicate, except for Tramadol and O-
desmethyltramadol, where the black curves are based on the range-finding test from a single replicate. Values 















Figure 3: Locomotor behaviour effects of opioids in zebrafish larvae. Locomotor activity was tracked in 5 
days post fertilization (dpf) larvae after immediate exposure to different concentrations of opioids (A-F). Data 
were obtained from three independent replicates with 8 larvae per treatment per replicate. Values are reported as 

















Figure 4: Uptake kinetics and biotransformation of butyrfentanyl (BF) in zebrafish larvae. Larvae at 5 dpf 
were exposed to 5 µM BF up to 10 h. At different time points during the uptake, butyrfentanyl and metabolites in 
the whole-body homogenates were measured by LC-MS/MS. Data were obtained from two independent 
replicates with each replicate containing 16 pooled fish per time point. Symbols represent experimental data; 
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 Zebrafish early life stages respond to synthetic opioids like rodents 
 Fentanyl derivatives were the most potent among the tested opioids 
 Pharmacokinetic parameters correlated with opioid effects  
 Zebrafish early life stages can serve as screening tool for opioid effects 
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